王倩,吳鵬波,李明,羅和生,余媛潔,譚詩云,舒泳翔(武漢大學人民醫(yī)院,武漢430060)
?
VEGF基因多態(tài)性及吸煙在誘發(fā)非酒精性脂肪肝中的交互作用
王倩,吳鵬波,李明,羅和生,余媛潔,譚詩云,舒泳翔(武漢大學人民醫(yī)院,武漢430060)
摘要:目的觀察非酒精性脂肪肝(NAFLD)患者血管內皮生長因子(VEGF)基因rs833061、rs3025039位點多態(tài)性,并探討其多態(tài)性及吸煙在誘發(fā)NAFLD中的交互作用。方法選擇NAFLD患者341例(NAFLD組)、健康體檢者246例(對照組),采用PCR-RFLP法分析VEGF基因rs833061、rs3025039位點基因型,非條件Logistic回歸分析法分析各基因型與NAFLD易感性的關系,非條件Logistic回歸分析法和廣義多因子降維法分析VEGF基因多態(tài)性及吸煙在誘發(fā)NAFLD中的交互作用。結果VEGF基因rs833061位點C基因攜帶者(CC+CT)罹患NAFLD的風險較非C基因攜帶者(TT)升高(P均<0.01),rs3025039位點T基因攜帶者(TT+CT)患病風險較非T基因攜帶者(CC)風險升高(P均<0.01)。VEGF基因rs833061位點多態(tài)性與吸煙可能在 NAFLD發(fā)病過程中存在相加作用(P<0.01),rs833061位點CC/CT基因型吸煙個體罹患NAFLD風險是攜帶TT基因型非吸煙個體的4.93倍。結論VEGF基因多態(tài)性與NAFLD發(fā)病有關,VEGF基因rs833061位點多態(tài)性與吸煙在誘發(fā)NAFLD過程中具有協(xié)同效應。
關鍵詞:非酒精性脂肪肝;血管內皮生長因子;基因多態(tài)性;易感性;交互作用
非酒精性脂肪肝(NAFLD)不僅可進展為肝硬化甚至肝癌,同時還可增加高血壓、糖尿病等的罹患風險[1,2]?,F(xiàn)已明確,遺傳因素在NAFLD發(fā)病過程中具有重要作用[3]。血管內皮生長因子(VEGF)可促進血管內皮細胞增殖、分化,增加血管通透性。此外,VEGF還具有調節(jié)能量代謝、胰島素抵抗以及炎癥反應等生物學效應[4,5]。研究發(fā)現(xiàn),吸煙不僅加劇胰島素抵抗,還可導致向心性肥胖[6]。而胰島素抵抗及向心性肥胖是NAFLD發(fā)病的重要危險因素。本研究探討NAFLD患者VEGF基因rs833061、rs3025039位點多態(tài)性及吸煙在誘發(fā)NAFLD中的交互作用。
1資料與方法
1.1臨床資料選擇2012年2月~2014年8月本院收治的NAFLD患者341例(NAFLD組),診斷標準符合《非酒精性脂肪性肝病診療指南(2010年修訂版)》[7]。其中,男210例、女131例,年齡(46.69±9.87)歲。同期另選在該院體檢健康者246例(對照組),男170例、女76例,年齡(47.65±11.36)歲。兩組基本資料比較見表1。
表1 兩組基本資料比較
注:HOMA-IR為胰島素抵抗指數(shù);與對照組比較,*P<0.05,△P<0.01。
1.2VEGF基因rs833061、rs3025039位點多態(tài)性檢測采用PCR-RFLP法。所有研究對象抽取空腹靜脈血,采用酚-氯仿法提取基因組DNA。根據(jù)VEGF-9及VEGF-2基因的核苷酸序列設計引物,采用PCR擴增目的基因片段。VEGF基因rs833061位點引物序列:上游引物:5′-CTCTTTAGCCAGAGCCGGGG-3′,下游引物:5′-TGGCCTTCTCCCCGCTCCGAC-3′;VEGF基因rs3025039位點引物序列:上游引物5′-AGGGTTCGGGAACCAGATC-3′,下游引物5′-CTCGGTGATTTAGCAGCAAG-3′。PCR反應體系25 μL,包括DNA 100 ng、1.0 U Taq酶、2 μL上下游引物、2×PCR buffer;PCR反應條件:94 ℃ 5 min,94 ℃ 30 s、60 ℃ 30 s、72 ℃ 45 s,30個循環(huán),最后72 ℃延伸10 min。限制性內切酶BsaHⅠ、NlaⅢ酶切。酶切產物經3%瓊脂糖凝膠電泳,EB染色成像,判定酶切基因型。
2結果
2.1VEGF基因rs833061、rs3025039位點基因型VEGF基因rs833061位點TT基因型片段長度為230、75 bp(75 bp片段太小,跑出膠外),CT基因型片段長度為290、230 bp,CC基因型片段長度為290 bp。VEGF基因rs3025039位點TT基因型片段長度為195 bp(25 bp片段太小,跑出膠外),CC基因型片段長度為195、170 bp,CT基因型片段長度為170 bp。
2.2兩組VEGF基因rs833061、rs3025039位點基因型分布及其與NAFLD易感性的關系兩組VEGF基因rs833061、rs3025039位點基因型分布見表2。相關分析顯示,VEGF基因rs833061位點C基因攜帶者(CC+CT)罹患NAFLD的風險是非C基因攜帶者(TT)的1.56倍(95%CI為1.12~2.15,P<0.05);校正吸煙、腰圍、血糖等因素后,C基因攜帶者(CC+CT)是非C基因攜帶者(TT)的1.71倍(95%CI為1.42~2.22,P<0.01)。VEGF基因rs3025039位點T基因攜帶者(TT+CT)罹患NAFLD的風險是非T基因攜帶者(CC)的1.61倍(95%CI為1.15~2.26,P<0.05);校正吸煙、腰圍、血糖等因素后,T基因攜帶者(TT+CT)罹患NAFLD的風險是非T基因攜帶者(CC)的1.83倍(95%CI為1.35~2.71,P<0.01)。
表2 兩組VEGF基因rs833061、rs3025039
2.3VEGF基因rs833061、rs3025039位點多態(tài)性與吸煙對誘發(fā)NAFLD的交互作用VEGF基因rs833061位點多態(tài)性+吸煙模型具有最大的預測正確率(0.668 8)和最高的交叉驗證一致性(10/10),為最優(yōu)模型。說明二者存在交互作用。與攜帶VEGF基因rs833061位點TT基因型不吸煙者相比,攜帶VEGF基因rs833061位點CT/CC基因型不吸煙者罹患NAFLD的風險增加2.22倍(P<0.01),攜帶VEGF基因rs833061位點TT基因型吸煙者罹患NAFLD風險增加1.82倍(P<0.01),攜帶VEGF基因rs833061位點CT/CC基因型吸煙者罹患NAFLD風險增加4.93倍(P<0.01) ;VEGF基因rs833061位點多態(tài)性與吸煙對誘發(fā)NAFLD存在相加作用(P<0.01)。
3討論
近年研究證實,遺傳因素在NAFLD發(fā)病中發(fā)揮重要作用[3]。人類VEGF基因位于染色體6p21.3,其蛋白表達水平在不同個體間有一定差異,這可能與VEGF基因多態(tài)性有關[9]。VEGF基因多態(tài)性位點主要位于5′非翻譯區(qū)和3′非翻譯區(qū)。研究發(fā)現(xiàn),VEGF基因多態(tài)性與肥胖、多囊卵巢綜合癥易感性相關[10,11],而肥胖及多囊卵巢綜合癥與脂肪肝在易感基因方面存在一定相似性[12,13]。因此,VEGF基因多態(tài)性可能與NAFLD發(fā)病有關。
本文通過病例對照分析發(fā)現(xiàn),以TT為參照,VEGF基因rs833061位點攜帶CT、CC基因型個體罹患NAFLD的風險增加;以CC為參照,VEGF基因rs3025039位點攜帶CT、TT基因型個體罹患NAFLD的風險增加。Logistic回歸校正腰圍、血糖、HDL-C、HOMA-IR及吸煙等因素后,仍發(fā)現(xiàn)rs833061、rs3025039位點多態(tài)性對NAFLD易感性有顯著影響。
NAFLD發(fā)病是個體遺傳因素與外界環(huán)境因素共同作用的結果。吸煙是NAFLD發(fā)生的危險因素,吸煙個體罹患NAFLD的風險增加25%[11]。本研究采用GMDR法分析VEGF基因rs833061、rs3025039位點多態(tài)性與吸煙對誘發(fā)NAFLD的交互作用。GMDR法是研究基因-基因以及基因-環(huán)境交互作用的一種可靠方法[12]。結果提示,rs833061位點多態(tài)性和吸煙在NAFLD發(fā)病中存在交互作用,而rs3025039位點多態(tài)性與吸煙則無交互作用。進一步采用非條件Logistic回歸分析法及Bootstrap法[14]對上述結果加以驗證,結果提示rs833061位點多態(tài)性和吸煙存在相加作用,但二者相加作用的機制目前尚不清楚。Fesinmeyer等[15]研究認為,吸煙可能是通過改變rs833061位點多態(tài)性協(xié)同增加NAFLD易感性。
綜上所述, VEGF基因rs833061、rs3025039位點多態(tài)性與NAFLD發(fā)病有關,VEGF基因rs833061位點多態(tài)性與吸煙在誘發(fā)NAFLD過程中具有相加作用,但上述結果仍需擴大樣本量進一步證實。
參考文獻:
[1] Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease[J]. World J Hepatol, 2014,6(11):800-811.
[2] 周歆,侯冬青,段佳麗,等.北京市387名肥胖中學生非酒精性脂肪肝等代謝異常罹患狀況調查[J].中華流行病學雜志,2013,34(5):446-450.
[3] Li L, Wang SJ, Shi K, et al. Correlation between MTP -493G>T polymorphism and non-alcoholic fatty liver disease risk: a meta-analysis[J]. Genet Mol Res, 2014,13(4):10150-10161.
[4] Elias I, Franckhauser S, Bosch F. New insights into adipose tissue VEGF-A actions in the control of smoking and insulin resistance[J]. Adipocyte, 2013,12(2):109-112.
[5] Amarapurkar AD, Amarapurkar DN, Vibhav S, et al. Angiogenesis in chronic liver disease[J]. Ann Hepatol, 2007,6(3):170-173.
[6] Chiolero A, Faeh D, Paccaud F, et al. Consequences of smoking for body weight, body fat distribution, and insulin resistance[J]. Am J Clin Nutr, 2008,87(4):801-809.
[7] 中華醫(yī)學會肝臟病學分會脂肪肝和酒精性肝病學組.非酒精性脂肪性肝病診療指南(2010年1月修訂版)[J].中華內科雜志,2010,49(3):275-278.
[8] 陳卿,唐迅,胡永華,等.應用廣義多因子降維法分析數(shù)量性狀的交互作用[J].中華流行病學雜志,2010,31(8):938-941.
[9] Rahoui J, Sbitti Y, Touil N, et al. The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women[J]. Med Oncol, 2014,31(12):336.
[10] Belo VA, Souza-Costa DC, Luizon MR, et al. Vascular endothelial growth factor haplotypes associated with childhood smoking[J]. DNA Cell Biol, 2011,30(9):709-714.
[11] Lee EJ, Oh B, Lee JY, et al. Association study between single nucleotide polymorphisms in the VEGF gene and polycystic ovary syndrome[J]. Fertil Steril, 2008,89(6):1751-1759.
[12] Kuliczkowska Plaksej J, Laczmanski L, Milewicz A, et al. Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controls[J]. Int J Endocrinol, 2014,2014:232975.
[13] Bohdanowicz-Pawlak A, Lenarcik-Kabza A, Brona A, et al. Non-alcoholic fatty liver diseasein women with polycystic ovary syndrome-clinical and metabolic aspects and lipoprotein lipase gene polymorphism [J]. Endokrynol Pol, 2014,65(6):416-421.
[14] Zhang LW, Li JP, Duan FF, et al. Interaction of type 2 diabetes mellitus with chromosome 9p21 rs10757274 polymorphism on the risk of myocardial infarction: a case-control study in Chinese population[J]. BMC Cardiovasc Disord, 2014(14):170.
[15] Fesinmeyer MD, North KE, Lim U, et al. Effects of smoking on the genetic risk of smoking: the population architecture using genomics and epidemiology study[J]. BMC Med Genet, 2013(14):6.
Gene polymorphism of VEGF and its interaction with smoking in patients with non-alcoholic fatty liver disease
WANGQian,WUPengbo,LIMing,LUOHesheng,YUYuanjie,TANShiyun,SHUYongxiang
(RenminHospitalofWuhanUniversity,Wuhan430060,China)
Abstract:ObjectiveTo observe the gene polymorphisms of vascular endothelial growth factor (VEGF) rs833061 and rs3025039 and to investigate their interaction with smoking in patients with non-alcoholic fatty liver disease (NAFLD). MethodsGenotypes of VEGF rs833061 and rs3025039 in 341 patients with NAFLD (NAFLD group) and 246 control subjects (control group) were examined by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). The unconditional logistic regression (ULR) was performed to analyze the relationships between the genotypes and susceptibility to NAFLD. The interactions between genotypes of VEGF rs833061 and rs3025039 and smoking in inducing NAFLD were explored by generalized multifactor dimensionality reduction (GMDR) and unconditional Logistic regression method. ResultsThe risk of NAFLD in VEGF rs833061 with genotype C (CC+CT) was higher than that of carriers without C (TT) (all P<0.01), and the risk of NAFLD in rs3025039T gene carriers (TT+CT) was higher than that of carriers without genotype T (CC) (all P<0.01). Gene polymorphism of VEGF rs833061 had interactions with smoking in the process of NAFLD (P<0.01). The risk of NAFLD in rs833061 CC/CT genotype of smoking individuals was 4.93 times higher than that of TT genotype of non-smoking individuals. ConclusionsVEGF gene polymorphism is associated with the risk of NAFLD. VEGF rs833061 and smoking have synergistic effects in the process of inducing NAFLD.
Key words:non-alcoholic fatty liver disease; vascular endothelial growth factor; gene polymorphisms; susceptibility; interaction
(收稿日期:2015-07-24)
中圖分類號:R575.5
文獻標志碼:A
文章編號:1002-266X(2016)08-0007-03
doi:10.3969/j.issn.1002-266X.2016.08.003
通信作者簡介:譚詩云(1962-),男,主任醫(yī)生,教授,研究方向為肝臟相關疾病的基礎與臨床。E-mail: tanshiyun@126.com
作者簡介:第一王倩(1989-),女,碩士在讀,研究方向為非酒精性脂肪肝的診治。E-mail: 1028578861@qq.com
基金項目:湖北省自然科學基金重點項目(2014CFA045)。